# US 2002/0055140 A1 · Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055140 A1
- Document ID: US20020055140A1
- Status: Published application
- Kind: A1
- Application number: 09/826,463
- Filed: 2001-04-05
- Published: 2002-05-09
- Earliest claimed: 1995-06-07
- Inventors: Nobuto Yamamoto
- Web page: https://patentgrep.com/patent/US20020055140A1

## CPC

- C07K 14/57: IFN-gamma
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Q 1/34: involving hydrolase
- C12Y 302/01049: Alpha-N-acetylgalactosaminidase (3.2.1.49)
- G01N 33/56983: {Viruses}
- G01N 33/56988: {HIV or HTLV}
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/575: for cancer
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C12N 2799/026: where the vector is derived from a baculovirus
- G01N 2333/16: HIV-1, HIV-2
- Y10S 436/813: Cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Vitamin D-binding protein (Gc protein) and its small domain (approximately ⅕ of the Gc peptide also known as domain III) were cloned via a baculovirus vector. The cloned Gc protein and the cloned domain (Cd) peptide were treated with immobilized β-galactosidase and sialidase to yield macrophage activating factors, GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAF are to be used for therapy of cancer, HIV-infection and osteopetrosis, and may also be used as adjuvants for immunization and vaccination.

## Claims

### Claim 1

A process for cloning vitamin D3-binding protein (Gc protein) into baculovirus comprising the step of selecting and using a baculovirus vector to clone the vitamin D3-binding protein Gc protein (Gc protein).

### Claim 2

A process for producing a cloned macrophage activating factor (GcMAFc) comprising contacting cloned Gc protein in vitro with immobilized β-galactosidase and sialidase and obtaining the cloned macrophage activating factor (GcMAFc).

### Claim 3

A process for cloning vitamin D3-binding protein domain III (Gc domain III) into baculovirus comprising the step of selecting and utilizing a baculovirus vector to clone the vitamin D3-binding protein domain III (Gc domain III).

### Claim 4

A process for producing a cloned macrophage activating factor (CdMAF) comprising contacting cloned Gc domain III in vitro with immobilized β-galactosidase and sialidase and obtaining the macrophage activating factor (CdMAF).

### Claim 5

A method of treating a person suffering from cancer by administering to the person a therapeutically effective amount of a Gc protein macrophage activating factor (GcMAF), the GcMAF being a product of contacting serum Gc protein in vitro with immobilized β-galactosidase and sialidase.

### Claim 6 (depends on 2)

A method of treating a person suffering from cancer by administering to the person a therapeutically effective amount of a cloned macrophage activating factor (GcMAFc), which is a product of the process according to claim 2.

### Claim 7 (depends on 4)

A method of treating a person suffering from cancer by administering to the person a therapeutically effective amount of a cloned macrophage activating factor (CdMAF), which is a product of the process according to claim 4.

### Claim 8

A method of treating a person suffering from human immunodeficiency virus (HIV), Epstein-Barr virus (EBV) or herpes zoster by administering to the person a therapeutically effective amount of a macrophage activating factor (GcMAF), which is a product of contacting serum Gc protein in vitro with immobilized β-galactosidase and sialidase.

### Claim 9 (depends on 2)

A method of treating a person suffering from human immunodeficiency virus (HIV), Epstein-Barr virus (EBV) or herpes zoster by administering to the person a therapeutically effective amount of a macrophage activating factor (GcMAFc), which is a product of the process according to claim 2.

### Claim 10 (depends on 4)

A method of treating a person suffering from human immunodeficiency virus (HIV), Epstein-Barr virus (EBV) or herpes zoster by administering to the person a therapeutically effective amount of a macrophage activating factor (CdMAF), which is a product of the process according to claim 4.

### Claim 11 (depends on 2)

A macrophage activating factor (GcMAFc), which is a product of the process according to claim 2.

### Claim 12 (depends on 4)

A macrophage activating factor (CdMAF), which is a product of the process according to claim 4.

### Claim 13 (depends on 2)

A method of promoting bone marrow formation in osteopetrotic patients comprising administering a therapeutically effective amount of a macrophage activating factor (GcMAFc), which is a product of the process according to claim 2.

### Claim 14 (depends on 4)

A method of promoting bone marrow formation in osteopetrotic patients comprising administering a therapeutically effective amount of a macrophage activating factor (CdMAF), which is a product of the process according to claim 4.

### Claim 15

An adjuvant for immunizing humans and animals with antigens or vaccines, the adjuvant comprising a macrophage activating factor (GcMAF) which is a product of contacting serum Gc protein in vitro with immobilized β-galactosidase and sialidase.

### Claim 16 (depends on 2)

An adjuvant for immunizing humans and animals with antigens or vaccines, the adjuvant comprising a macrophage activating factor (GcMAFc), which is a product of the process according to claim 2.

### Claim 17 (depends on 4)

An adjuvant for immunizing humans and animals with antigens or vaccines, the adjuvant comprising a macrophage activating factor (CdMAF), which is a product of the process according to claim 4.

### Claim 18

A cloned vitamin D3-binding protein (Gc protein) having an amino acid sequence of FIG. 3 (SEQ. ID. NO:1)(GcMAFc).

### Claim 19

A cloned vitamin D3-binding protein domain III (Gc domain III) having an amino acid sequence of FIG. 5 (SEQ ID. NO:2)(CdMAF1).

### Claim 20

A cloned vitamin D3-binding protein domain III (Gc domain II) having an amino acid sequence of FIG. 7 (SEQ ID. NO:3)(CdMAF2).
